{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:51:06Z","timestamp":1790661066494,"version":"4.1.0"},"reference-count":15,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Biochemistry"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.clinbiochem.2019.04.009","type":"journal-article","created":{"date-parts":[[2019,4,13]],"date-time":"2019-04-13T18:40:54Z","timestamp":1555180854000},"page":"50-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Commonly used fluoroquinolones cross-react with urine drug screens for opiates, buprenorphine, and amphetamines"],"prefix":"10.1016","volume":"68","author":[{"given":"Jennifer M.","family":"Colby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pratish C.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darwin Y.","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola J.","family":"Rutherford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinbiochem.2019.04.009_bb0005","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/jat\/bku075","article-title":"False-positive interferences of common urine drug screen immunoassays: a review","volume":"38","author":"Saitman","year":"2014","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.clinbiochem.2019.04.009_bb0010","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/bs.acc.2016.11.003","article-title":"Rapid assessment of drugs of abuse","volume":"80","author":"Wiencek","year":"2017","journal-title":"Adv. Clin. Chem."},{"key":"10.1016\/j.clinbiochem.2019.04.009_bb0015","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1373\/jalm.2017.024893","article-title":"Challenges in interpreting unexpected urine drug test results","volume":"2","author":"Heger","year":"2018","journal-title":"J. Appl. Lab. Med. AACC Publ."},{"key":"10.1016\/j.clinbiochem.2019.04.009_bb0020","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/jat\/bkv133","article-title":"A retrospective analysis of urine drugs of abuse immunoassay true positive rates at a national reference laboratory","volume":"40","author":"Johnson-Davis","year":"2016","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.clinbiochem.2019.04.009_bb0025","first-page":"42","article-title":"False-positive TDxFLx urine amphetamine\/Metamphetamine II assay from Ofloxacin","volume":"12","author":"Nomier","year":"2004","journal-title":"Saudi Pharma. J."},{"key":"10.1016\/j.clinbiochem.2019.04.009_bb0030","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/00007691-199702000-00019","article-title":"False-positive EMIT II opiates from ofloxacin","volume":"19","author":"Meatherall","year":"1997","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.clinbiochem.2019.04.009_bb0035","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1001\/jama.286.24.3115","article-title":"Quinolones and false-positive urine screening for opiates by immunoassay technology","volume":"286","author":"Baden","year":"2001","journal-title":"JAMA."},{"key":"10.1016\/j.clinbiochem.2019.04.009_bb0040","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1503\/cmaj.091508","article-title":"Urine opiate screening: false-positive result with levofloxacin","volume":"182","author":"Shafiq","year":"2010","journal-title":"Can. Med. Assoc. J."},{"key":"10.1016\/j.clinbiochem.2019.04.009_bb0045","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1093\/bioinformatics\/btn307","article-title":"ChemmineR: a compound mining framework for R","volume":"24","author":"Cao","year":"2008","journal-title":"Bioinformatics."},{"key":"10.1016\/j.clinbiochem.2019.04.009_bb0050","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1369-1600.2000.tb00197.x","article-title":"Ofloxacin causes false-positive immunoassay results for urine opiates","volume":"5","author":"Backmund","year":"2000","journal-title":"Addict. Biol."},{"key":"10.1016\/j.clinbiochem.2019.04.009_bb0055","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ijantimicag.2004.01.013","article-title":"Urinary concentrations and bactericidal activities of newer fluoroquinolones in healthy volunteers","volume":"24","author":"Stein","year":"2004","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.clinbiochem.2019.04.009_bb0060","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2147\/SAR.S88935","article-title":"Cross-reactivity of the CEDIA buprenorphine assay in drugs-of-abuse screening: influence of dose and metabolites of opioids","author":"Berg","year":"2015","journal-title":"Subst. Abus. Rehabil."},{"key":"10.1016\/j.clinbiochem.2019.04.009_bb0065","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/jat\/bks003","article-title":"A new highly specific buprenorphine immunoassay for monitoring buprenorphine compliance and abuse","volume":"36","author":"Melanson","year":"2012","journal-title":"J. Anal. Toxicol."},{"key":"10.1016\/j.clinbiochem.2019.04.009_bb0070","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1021\/acs.jcim.7b00418","article-title":"Predictive power of different types of experimental restraints in small molecule docking: a review","volume":"58","author":"Fu","year":"2018","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.clinbiochem.2019.04.009_bb0075","series-title":"Opiates Package Insert REF 3L34\u201320","author":"Diagnostics","year":"2014"}],"container-title":["Clinical Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000991201930092X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000991201930092X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T15:53:47Z","timestamp":1757865227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000991201930092X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":15,"alternative-id":["S000991201930092X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2019.04.009","relation":{},"ISSN":["0009-9120"],"issn-type":[{"value":"0009-9120","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Commonly used fluoroquinolones cross-react with urine drug screens for opiates, buprenorphine, and amphetamines","name":"articletitle","label":"Article Title"},{"value":"Clinical Biochemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinbiochem.2019.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}